Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Mike Novogratz

Data updated

New York City, United States

Mike Novogratz is an American investor and the founder and CEO of Galaxy, where he leads a global digital-assets and blockchain-focused investment platform. Public company filings list his principal business address in New York City, and Galaxy’s headquarters is also reported as New York City.

He matters to the psychedelic ecosystem mainly as a public backer of psychedelic biopharma through atai Life Sciences, where investor lists and commentary name him among notable investors. Public references also link Novogratz to the broader psychedelic investment network alongside other prominent financiers involved in drug-development and mental-health innovation.

Investor Context

Angel Investors

Investment Context

This stakeholder is listed as an Angel Investor within Angel Investors. Its public geography context is global. Public stage signals include Seed and Series A/B. Public focus areas include Drug Development.

Public Portfolio Examples

Mike Novogratz is best described as a founder-operator investor with a global orientation through Galaxy and a separately documented interest in psychedelic medicine investing. Public materials place him in the orbit of atai Life Sciences and related biotech financing, suggesting relevance to psychedelic drug development rather than a dedicated psychedelic fund strategy. His public profile is strongest around large-scale alternative assets, but he also appears in investor syndicates tied to neuropsychiatry and psychedelic therapeutics.

Investor Type

Angel Investor

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/B

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Angel Investor

Investment Website

Recorded Investments

private placement - undisclosed

Public announcement identifies Mike Novogratz among ATAI investors; relevant to psychedelic drug development.

ATAI Life Sciences and Cyclica launch AI-enabled psychedelics lab to revolutionize drug development for mental health disorders

Quick Facts

Founded
2018
HQ
New York City, United States
Website
Visit